Immunovant, Inc. (IMVT) stock
IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$33.21−0.07 (-0.21%)
Close on Nov 17, 2026Market cap $6.86BP/E –Yield –
Immunovant EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Immunovant's EPS for the twelve months ending Jun 30, 2026 was -$2.82. For fiscal 2026 it was -$2.77. The highest annual figure on record is -$1.22 in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$2.77 | – |
| FY2025 | Mar 31, 2025 | -$2.73 | – |
| FY2024 | Mar 31, 2024 | -$1.88 | – |
| FY2023 | Mar 31, 2023 | -$1.71 | – |
| FY2022 | Mar 31, 2022 | -$1.43 | – |
| FY2021 | Mar 31, 2021 | -$1.22 | – |
| FY2020 | Mar 31, 2020 | -$1.54 | – |
| FY2019 | Mar 31, 2019 | -$1.29 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -$0.75 | – |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -$0.73 | – |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$0.61 | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -$0.73 | – |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -$0.71 | – |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -$0.64 | – |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$0.76 | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -$0.74 | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -$0.60 | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -$0.52 | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$0.36 | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$0.45 | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$0.57 | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -$0.46 | – |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$0.49 | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$0.41 | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$0.35 | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -$0.41 | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$0.36 | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -$0.35 | – |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$0.31 | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$0.29 | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$0.32 | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -$0.25 | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -$0.38 | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$0.56 | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$0.52 | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $0.00 | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -$0.24 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?